From : Robert Gish <rgish@robertgish.com>
To : Undisclosed recipients:; Undisclosed
Subject : new article - "Hepatitis B Core Antibody: Role in Clinical Practice in 2020"
Received On : 13.07.2020 15:51
Thank you all for input from colleagues in the hepatology community to help update all providers on the facts about anti-HBc.

You can read the newly published article here:

https://rdcu.be/b5zpZ


2 key take-away points

 

False + rate for current anti-HBc testing is 2/1,000

 

Anti-HBc + (total) test = cccDNA

                Risk for reactivation

                No need for HBV vaccine

                Consider evaluation for OBI in clinical setting of anti-HBc alone

 

There is no current peer reviewed data that patients clear cccDNA after acute HBV and total anti-HBc+ tracks the presence of cccDNA

 

Cautious use of anti-HBc IgM use in clinical practice to diagnose and manage “acute HBV”

 

Thank you,

Robert G. Gish MD

+1 858 229 9865